Literature DB >> 34344998

Kinase inhibitor combination combats liver cancer.

Sarah Crunkhorn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34344998     DOI： 10.1038/d41573-021-00132-5

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  1 in total

1.  EGFR activation limits the response of liver cancer to lenvatinib.

Authors:  Haojie Jin; Yaoping Shi; Yuanyuan Lv; Shengxian Yuan; Christel F A Ramirez; Cor Lieftink; Liqin Wang; Siying Wang; Cun Wang; Matheus Henrique Dias; Fleur Jochems; Yuan Yang; Astrid Bosma; E Marielle Hijmans; Marnix H P de Groot; Serena Vegna; Dan Cui; Yangyang Zhou; Jing Ling; Hui Wang; Yuchen Guo; Xingling Zheng; Nikita Isima; Haiqiu Wu; Chong Sun; Roderick L Beijersbergen; Leila Akkari; Weiping Zhou; Bo Zhai; Wenxin Qin; René Bernards
Journal:  Nature       Date:  2021-07-21       Impact factor: 49.962
  1 in total
  1 in total

Review 1.  Small Molecule Inhibitors for Hepatocellular Carcinoma: Advances and Challenges.

Authors:  Monica A Kamal; Yasmine M Mandour; Mostafa K Abd El-Aziz; Ulrike Stein; Hend M El Tayebi
Journal:  Molecules       Date:  2022-08-28       Impact factor: 4.927
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.